A two arm phase I trial of sorafenib in combination with cisplatin/etoposide or carboplatin/pemetrexed in patients with solid tumors.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carboplatin; Cisplatin; Etoposide; Pemetrexed; Sorafenib
- Indications Solid tumours
- Focus Adverse reactions
- 24 Apr 2012 Biomarkers information updated
- 23 Apr 2012 Actual patient number is 31 according to ClinicalTrials.gov.
- 23 Apr 2012 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.